Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema (C1‑inhibitor deficiency) in patients who experience acute swelling attacks.

GNH USA supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Fresenius is a bradykinin B2 receptor antagonist used to manage hereditary angioedema attacks. It acts on the pathway that mediates swelling caused by excess bradykinin. - Hereditary angioedema (type I C1‑INH deficiency): provides rapid relief of acute swelling episodes. - Hereditary angioedema (type II C1‑INH deficiency): reduces severity and duration of attacks. - Hereditary angioedema with normal C1‑INH: offers symptom control during acute episodes.

Icatibant Fresenius may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, pruritus, or urticaria. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling in other areas. - Severe injection‑site necrosis: tissue damage at the site. - Thrombotic events: rare clot formation.

Before initiating therapy with Icatibant Fresenius, clinicians should consider several safety aspects. - Confirm diagnosis: ensure the patient has hereditary angioedema confirmed by laboratory testing. - Hypersensitivity: avoid use in individuals with known allergy to icatibant or any excipients. - Cardiovascular disease: monitor patients with unstable heart conditions due to potential blood‑pressure effects. - Pregnancy and lactation: safety has not been established; use only if the potential benefit outweighs risk. - Concomitant ACE‑inhibitors: be aware of additive bradykinin effects that may increase angioedema risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Fresenius can interact with other medicines that influence the bradykinin pathway or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin‑mediated angioedema. - Other bradykinin B2 antagonists: concurrent use can lead to unpredictable pharmacodynamics.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: can increase frequency of HAE attacks. - C1‑inhibitor concentrate: may reduce the need for icatibant in some patients. - DPP‑4 inhibitors: theoretical risk of altered bradykinin metabolism. - Diuretics: monitor blood pressure due to possible additive hypotensive effect.